Literature DB >> 21791972

Should the chickenpox vaccine be included in the National Immunization Schedule in India?

Ramesh Verma1, Mohan Bairwa, Suraj Chawla, Shankar Prinja, Meena Rajput.   

Abstract

Varicella (chickenpox) is an acute, highly contagious viral disease with worldwide distribution. The highest prevalence occurs in the 4-10 year age group but tends to be more severe in adults. It may be fatal in neonates, immunocompromised persons, and normal adults, especially smokers. Varicella is usually a benign childhood disease, and rarely rated as an important public health problem, but this can be severe and even fatal in otherwise healthy children (< 1 out of every 10,000 cases). Chickenpox can cause pneumonia (23 out of every 10,000 cases), and is an important risk factor for developing severe invasive "strep" (group A streptococcal disease). Complications of varicella include bacterial infections (up to 5% of cases), decreased platelets, arthritis, hepatitis, pneumonia (more commonly in adults) or encephalitis (1 in 10,000 cases), which may cause a failure of muscular coordination, sometimes resulting in persistent sequelae or death. Varicella is the leading cause of vaccine-preventable death in children. Universal vaccination can cause a dramatic reduction in the incidence of varicella, associated complications, hospitalizations and fatality rates. In India, due to the high cost of the vaccine, it would be difficult to vaccinate a large percentage of the children. The government of India should consider the inclusion of varicella vaccine in the National Immunization Schedule with the help of International agencies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21791972     DOI: 10.4161/hv.7.8.15685

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  4 in total

1.  Safety and immunogenicity of single dose live attenuated varicella vaccine (VR 795 Oka strain) in healthy Indian children: a randomized controlled study.

Authors:  Monjori Mitra; Mma Faridi; Apurba Ghosh; Nitin Shah; Raju Shah; Suparna Chaterjee; Manish Narang; Nisha Bhattacharya; Gandhali Bhat; Harish Choudhury; Ganesh Kadhe; Amey Mane; Sucheta Roy
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Clinico-epidemiological investigation on Varicella Zoster Virus indicates multiple clade circulation in Maharashtra state, India.

Authors:  Rima R Sahay; Pragya D Yadav; Triparna Majumdar; Swapnil Patil; Prasad Sarkale; Anita M Shete; Gouri Chaubal; Vinay R Dange; Savita Patil; Dimpal A Nyayanit; Jayanthi Shastri; Devendra T Mourya
Journal:  Heliyon       Date:  2018-08-28

3.  The Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Slovenia.

Authors:  Colleen Burgess; Stephanie Kujawski; Ajda Lapornik; Goran Bencina; Manjiri Pawaskar
Journal:  J Health Econ Outcomes Res       Date:  2022-09-20

4.  Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.

Authors:  Sanjay Lalwani; Sukanta Chatterjee; Sundaram Balasubramanian; Ashish Bavdekar; Shailesh Mehta; Sanjoy Datta; Michael Povey; Ouzama Henry
Journal:  BMJ Open       Date:  2015-09-11       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.